# A Research Study to Evaluate the Safety of R306465, a Drug in Development for Cancer and to Study the Absorption, Break Down and Elimination in Patients With Advanced Solid Malignancies.

> **NCT00677001** · PHASE1 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 15 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** R306465

## Key facts

- **NCT ID:** NCT00677001
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** —
- **Final completion:** 2006-10
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2010-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00677001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00677001, "A Research Study to Evaluate the Safety of R306465, a Drug in Development for Cancer and to Study the Absorption, Break Down and Elimination in Patients With Advanced Solid Malignancies.". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00677001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*